Actively Recruiting
Evaluating Real-World Use and Outcomes of TAR-200 in Non-Muscle Invasive Bladder Cancer Across US Clinical Settings
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
150
Participants Needed
23
Research Sites
64 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how well TAR-200 works in everyday medical practice for people with non-muscle invasive bladder cancer NMIBC, an early-stage bladder cancer limited to the bladders inner lining. The study focuses on measuring the time from when participants first receive TAR-200 until their cancer worsens or symptoms return, known as disease-free survival. Participants who have started their first dose of TAR-200 within six weeks before the initial study visit are observed without receiving any new interventions. They will be followed for up to 24 months, or until they die, are lost to follow-up, or withdraw consent. This observational study takes place in real-world clinical settings across multiple centers in the United States. During the study, participants will have their health monitored regularly to track outcomes such as complete response rates, duration of response, overall survival, cancer-specific survival, time to next treatment, and any adverse events. Researchers will also observe treatment patterns, adherence, and outcomes after any re-treatment with TAR-200. The total participation lasts up to 24 months, with data collected to understand long-term effects and safety.
CONDITIONS
Brief Title
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
Research Team
S
Study Contact
E
Eliza M. Raymundo, MD, DMCC, FPUA, FPCS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here